Aptevo awarded $1.5M non-dilutive grant from Andy Hill CARE Fund for APVO451 IND-enabling studies

Aptevo Therapeutics Inc.

Grant of $1,499,951 from Andy Hill Cancer Research Endowment (CARE) Fund to support IND-enabling studies for APVO451, a trispecific antibody targeting nectin-4, CD40, and CD3 for solid tumors.
Funding is non-dilutive and on a reimbursement basis; project period through June 2028, subject to milestones and matching contributions.
APVO451 advancing toward development candidate selection by year-end 2026 and IND-enabling studies in Q1 2027.
Grant provides external validation of APVO451's trispecific design and supports Aptevo's solid tumor immunotherapy efforts.
Aptevo retains IP ownership; grant includes customary terms including acknowledgment and commercialization commitments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.